A similar clinical trial is also currently ongoing in the US and in Europe with a novel autologous CD19-targeting CAR-T cell manufactured using the T-ChargeTM Platform (YTB323) for the treatment of R/R CD19-positive lymphoid neoplasms. Here, CD19 is linked to lymphoid neoplasm.